Pothuri B, Brodsky AL, Sparano JA, Blank SV, et al. Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up. Cancer Chemother Pharmacol 2020 Feb 13. pii: 10.1007/s00280-020-04030.
PMID: 32055930